BUY PEG MGF 2 mg/Vial | Research Peptide | Hilma Biocare

MAIN PRODUCT DESCRIPTION
Product Overview & Pharmaceutical Specifications

PEG MGF (2 mg/vial – 1 vial) is a peptide preparation described in the supplied information as Pegylated Mechano Growth Factor (PEG MGF). The source relates PEG MGF to mechano growth factor (MGF), an IGF-related peptide involved in research into skeletal muscle biology and cellular signalling.

The product is presented as a 2 mg lyophilised powder per vial and is explicitly classified as research use only. The supplied information discusses experimental interest in muscle-cell signalling, PEGylation and peptide pharmacokinetics.

Product Specifications

Product: PEG MGF
Unit Size: 2 mg per vial
Active Compound: Pegylated Mechano Growth Factor
Sequence supplied: Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys
Molecular Formula supplied: C121H200N42O39
Molecular Weight supplied: 2888.16 g/mol
CAS Number: N/A
Physical State: Lyophilised powder
Route: Injection, according to supplied information
Market Status: Research use only
Manufacturer: Hilma Biocare
Distributor: Rein Farmacie, Belgium
Storage: 2–8°C; do not freeze; protect from direct sunlight
Biological Background

Mechano growth factor is discussed in the supplied material as an IGF-related peptide associated with cellular processes involved in skeletal muscle adaptation.

The source describes MGF in relation to myoblast proliferation and muscle-fibre development. Myoblasts are precursor cells involved in the formation and repair of skeletal muscle fibres.

The supplied information contrasts MGF with other IGF-1-related signalling mechanisms and states that MGF can influence myoblast activity through different receptor pathways.

These statements describe biological and research concepts rather than an established therapeutic indication for PEG MGF.

PEGylation

PEG MGF incorporates PEGylation, a process in which a polyethylene glycol (PEG) group is attached to a peptide or protein.

PEGylation can alter several pharmaceutical characteristics, including molecular size, pharmacokinetics, circulation time and degradation. The supplied source states that PEGylation may increase peptide persistence and reduce the frequency with which a biologically active compound needs to be administered.

The precise effects of PEGylation depend on the molecular structure, attachment site, formulation and experimental conditions.

The supplied source also contains broad claims concerning the safety and regulatory use of PEG materials. These statements refer generally to PEG and should not be interpreted as establishing the safety or approval of the complete PEG MGF product.

IGF-Related Signalling

The supplied information associates PEG MGF with the broader insulin-like growth factor (IGF) signalling system.

IGF-1 is involved in cellular growth, differentiation and tissue regulation. Research involving MGF-related peptides has examined how local signalling within skeletal muscle may differ from systemic IGF-1 activity.

PEG MGF should not, however, be described as equivalent to recombinant human IGF-1 or as an approved growth-factor medicine.

Skeletal Muscle Research

One of the principal research areas described in the supplied material is skeletal muscle biology.

The source associates MGF-related activity with:

Myoblast proliferation
Muscle-fibre development
Muscle-cell recovery
Protein synthesis
Nitrogen retention
Skeletal muscle adaptation

These mechanisms are relevant to laboratory research into muscle physiology. They do not establish that PEG MGF produces a predictable increase in human muscle mass or strength.

The source contains a claim that MGF may improve muscle growth by approximately 25% within three weeks. No specific study citation or complete bibliographic reference supporting this numerical claim was supplied, so it has not been presented as an established clinical finding.

Research into Muscle Recovery

The supplied material describes PEG MGF as being investigated for potential effects on damaged muscle and muscle recovery.

Muscle repair involves coordinated processes including satellite-cell activity, protein synthesis, extracellular-matrix remodelling and inflammatory signalling.

MGF-related signalling is of scientific interest because of its potential involvement in some of these processes. However, the supplied product information does not establish PEG MGF as a clinically approved treatment for muscle injury, wasting or delayed recovery.

Other Proposed Effects

The original source lists several proposed benefits, including reduced body fat, improved endurance, immune effects, skin effects, stronger bones, cholesterol changes and increased recovery.

These statements are not supported by specific clinical references in the supplied information and therefore have not been presented as established therapeutic benefits.

The product should not be marketed as a proven treatment for obesity, cardiovascular disease, osteoporosis, immune disorders, ageing or athletic performance.

Pharmacokinetic Research

The supplied material states that PEGylation can provide a longer and more stable peptide presence in serum compared with non-pegylated forms.

This is one of the principal reasons PEGylation has been investigated in pharmaceutical development. Increasing molecular size and altering peptide degradation can potentially change absorption and elimination characteristics.

The specific pharmacokinetic profile of this PEG MGF preparation has not been supplied. No validated human half-life or serum concentration data have therefore been added.

Research Status

The product is explicitly identified as research use only.

The source describes experimental research involving MGF, PEGylation and muscle-related pathways but does not provide evidence of an approved therapeutic indication for PEG MGF.

Accordingly, it should not be represented as an authorised medicine for muscle wasting, injury recovery, muscle growth, fat loss, anti-ageing or athletic performance.

Administration Information

The supplied material contains experimental administration and dosage information, including microgram quantities, frequency and route.

Because PEG MGF is explicitly identified as research use only, those experimental dosing schedules have not been converted into instructions for human administration.

The stated 2 mg per vial is the amount of research material supplied and should not be interpreted as a therapeutic dose.

Possible Side Effects

The supplied source states that PEG MGF has not been thoroughly studied and reports possible:

Injection-site pain
Injection-site irritation
Itching
Soreness

The limited information available in the source does not establish a comprehensive clinical safety profile.

The absence of a long list of reported adverse reactions should not be interpreted as evidence that PEG MGF is free from systemic risks.

Safety Considerations

PEG MGF influences biological growth-factor-related pathways, and its full effects may depend on exposure, formulation and individual physiology.

The supplied information does not provide validated long-term human safety data, comprehensive contraindications or established drug-interaction information.

Accordingly, no claims that PEG MGF is safe, risk-free or suitable for routine human use have been made.

Manufacturer and Distribution

Manufactured by: Hilma Biocare

Distributed by: Rein Farmacie, Belgium

The supplied source does not provide a certificate of analysis, batch-specific testing results or regulatory authorisation documentation.

Scientific and Regulatory References

The supplied information refers generally to research involving MGF, PEGylation and neurological or muscle-related studies, but it does not provide complete PubMed records, DOI references or formal bibliographic citations.

No scientific references have therefore been fabricated or attributed to specific publications.

Regulatory Information

No EU marketing authorisation, national European marketing authorisation number or approved therapeutic indication was supplied for PEG MGF.

Therefore, no claim is made that the product is EU-authorised, prescription-only throughout Europe or legally saleable in any particular European country.

The product should be described consistently as research use only unless current authoritative regulatory documentation establishes otherwise.

Storage and Handling

The supplied storage requirements are:

Store at 2–8°C
Do not freeze
Protect from direct sunlight

The product is supplied as a lyophilised powder. Handling and laboratory preparation should follow appropriate procedures and the manufacturer’s current technical documentation.

Important Research Notice

PEG MGF is identified as a research-use-only peptide associated with MGF and IGF-related research. The supplied source discusses myoblast activity, skeletal muscle biology and PEGylation, but these findings do not establish clinical efficacy or safety in humans.

The product should not be presented as an approved treatment for muscle growth, injury recovery, fat loss, ageing or other medical conditions.

This product information is based solely on the supplied source material and does not replace professional medical advice, official prescribing information or regulatory documentation.